RxDoctor Payments Data

Anthony Ochoa, MD

Cardiovascular Disease · Traverse City, MINPI 1720060395

Payments from drug & device makers

$19,002in general payments, 2019–2025

Across 83 payments — averaging $228.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$10K
  • Boston Scientific$8K
  • Penumbra, Inc.$386
  • Abbott$267
  • Impulse Dynamics (USA) Inc.$180
  • Johnson & Johnson$114
  • plus $110 from 2 others

What the payments were for

  • Food & beverage$1,161100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,002 in reported general payments places this provider in the 75th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$164,808
Medicare patients
1,502
Services billed
3,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban430$495,488
XareltoRivaroxaban151$162,928
EntrestoSacubitril/Valsartan87$125,898
Repatha SureclickEvolocumab27$39,933
JardianceEmpagliflozin30$39,101
Repatha SyringeEvolocumab15$7,933
Metoprolol Succinate377$7,362
Atorvastatin Calcium314$5,862
Dabigatran EtexilateDabigatran Etexilate Mesylate27$4,358
Dofetilide24$3,987
Carvedilol247$3,446
Bumetanide79$3,359
Diltiazem 24hr Er (Cd)Diltiazem Hcl115$3,332
Flecainide Acetate64$3,246
Amiodarone Hcl73$3,171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$114$162,928151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Traverse City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →